Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Immix Biopharma (NASDAQ:IMMX) will present an abstract for NXC-201 at the American Society of Hematology 67th Annual Meeting, December 6-9, 2025, in Orlando, Florida. The company, focused on relapsed/refractory AL amyloidosis, announced participation and an abstract presentation slot at the conference.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, has announced its participation in the 37th Annual Piper Sandler Healthcare Conference.
The conference will take place on December 2-4, 2025 at the Lotte New York Palace Hotel in New York. The company will conduct institutional investor meetings and interested investors can arrange one-on-one meetings through their Piper Sandler representative. A replay of the presentation will be available on the company's website under the Investors section.
Immix Biopharma (NASDAQ:IMMX) has announced surpassing the 50% enrollment milestone in its NEXICART-2 clinical trial, evaluating NXC-201, a sterically-optimized CAR-T therapy for relapsed/refractory AL Amyloidosis.
The company is advancing toward its goal of achieving the first FDA-approved cell therapy Biologics License Application (BLA) for this orphan indication, where currently no FDA-approved treatments exist. The trial's interim results were presented at ASCO 2025 by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, with growing interest from clinicians and patients following the presentation.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has appointed Dr. Nancy T. Chang to its Board of Directors. Dr. Chang, former CEO of Tanox Inc., joins concurrent with her investment through Goose Capital.
Dr. Chang brings significant expertise, having led the development of several successful drugs including XOLAIR® for severe asthma, TROGARZO® for HIV, and EBGLYSS® for dermatitis. These drugs have collectively generated over $5 billion in sales. Notably, under her leadership, Tanox was acquired by Genentech/Roche for $919 million.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has secured a strategic investment from Goose Capital, led by former Tanox CEO Dr. Nancy T. Chang. Dr. Chang's track record includes developing successful FDA-approved drugs like XOLAIR®, TROGARZO®, and EBGLYSS®, which have collectively generated over $5 billion in sales.
The investment aims to support Immix's development of cell therapies for AL Amyloidosis and other serious diseases, particularly the commercialization of NXC-201 for relapsed/refractory AL Amyloidosis. This strategic partnership brings valuable expertise to Immix, as Dr. Chang has significant experience in bringing drugs from invention through FDA approval and commercialization.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, has announced its participation in the upcoming Stifel 2025 Healthcare Conference.
The conference will take place from November 11-13, 2025 at the Lotte New York Palace Hotel in New York. The company will conduct institutional investor meetings and one-on-one sessions during the event. Interested investors can arrange meetings through their Stifel representatives. A replay of the presentation will be available on the company's website under the Investors section.
Immix Biopharma (NASDAQ:IMMX) has announced its strategy for Other Serious Diseases (OSD) while advancing its lead BCMA-targeted CAR-T cell therapy, NXC-201. The company is currently conducting clinical trials for multiple serious diseases and plans to partner with external organizations to license out these OSD programs.
The company remains focused on completing the NEXICART-2 trial in relapsed/refractory AL Amyloidosis for Biologics License Application (BLA) submission. NXC-201 features a unique "digital filter" technology that filters out non-specific activation, potentially offering "one-and-done" treatment solutions. The company plans to present additional clinical data at upcoming scientific forums.
Immix Biopharma (NASDAQ:IMMX) announced promising safety data for its CAR-T therapy NXC-201, highlighting the absence of neurotoxicity in low-volume disease cases. The company is advancing its NEXICART-2 clinical trial towards a Biologics License Application (BLA) for treating relapsed/refractory AL Amyloidosis.
The therapy's favorable safety profile positions NXC-201 for potential expansion into other immune-mediated and serious diseases. Interim results were presented at ASCO 2025 by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, with the company maintaining focus on BLA submission for FDA approval.
Immix Biopharma (NASDAQ:IMMX) reported accelerated progress in its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis. The trial has expanded to 18 clinical trial sites nationwide, marking significant advancement toward becoming the first FDA-approved cell therapy for this orphan indication.
The company presented interim results at ASCO 2025, with Dr. Heather Landau of Memorial Sloan Kettering Cancer Center leading the presentation. The expansion addresses an urgent unmet need, as currently there are no FDA-approved drugs for this condition.